“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours where they can inhibit tumour growth and improve survival. We look forward to advancing this program(DX3) as an adjunct to our planned first in human clinical study of PAT-DX1, which remains on track for late 2022.”
This could be the trigger for a CR.........DX3 tickled someone's fancy and they want to be part of this...........someone throwing dollars at us but for this to happen we have been told to get a wriggle on.
My guess of course.................many options but this one sits well with me
“This preclinical study has shown that the affinity our...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2053666 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3325244 | 5 |
View Market Depth
| Last trade - 16.12pm 19/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable